About

Quick Facts  •  MAG200 to date  •  Directors and management team

Who are we

Magellan is a private Australian company with expertise in research, development and manufacturing of stem cells for the treatment of osteoarthritis.

We lead the way globally in scientific, clinical and commercial expertise for stem cell supply and development, for both autologous treatments which use the patient’s own cells, and allogeneic treatments which use selected donor cells. We have over ten years of stem cell commercial manufacturing expertise and have cultured more than 300 billion stem cells during this time.

Our vision is to improve and enrich the lives of people currently struggling with osteoarthritis across the globe, by significantly reducing pain and improving their mobility.

Our product, MAG200 will be an off-the-shelf product to reduce pain in people whose joints are affected by Osteoarthritis, potentially eliminating the need for joint replacement surgery.

Quick Facts

100M+ people in developed world (>500M globally) have OA

OA affects 20% of the population 45+ years old, and 80% of population 65+ yrs old

Limited short term pain improvement

No disease modification

Potential risk of significant side effects

Osteoarthritis is pharmaceutical therapeutics market growing rapidly 

Projected $7.3B+ USD per annum (2020) to $11B+ USD per annum by 2025

More than 1% per annum of GDP in developed nations

The average non-surgical medical cost per patient $5.9k USD per annum

Phase III for Clinical Efficacy Trial – commencing Q4 2023 

OA is the Number 1 National Health Priority (by value)

Suitable for accelerated regulatory pathways including Priority Review (TGA#)

Magellan Stem Cells product MAG200 to date

Pre-clinical research

Phase I & II for Clinical Safety and primary efficacy

Phase III for Clinical Efficacy Trial – beginning in 2025

Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence in 2025.

Magellan Stem cells has secured a laboratory in southeast Melbourne and commenced construction of a good manufacturing practice laboratory. This was completed in 2023. The lab is currently undergoing GMP accreditation with the TGA.

Our leading peer reviewed research and development has led to a world first publication using autologous (patient’s own) stem cell therapy in the successful management of Osteoarthritis. We are now undertaking the largest registered clinical trial with adipose derived mesenchymal stem cells therapy for Osteoarthritis in the world.

Directors and management team

Magellan Stem Cells has successfully built a laboratory in southeast Melbourne and it is currently undergoing TGA GMP accreditation with the aim to have the accreditation secured by second quarter 2024.

Board of Directors

Lou Panaccio
Non-Executive Chairman

Mr Panaccio is a Chartered Accountant with a wealth of executive management experience in business and healthcare services. Mr Panaccio has been the Chief Executive Officer of Monash IVF and Executive Director of Melbourne Pathology. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited.

Mr Panaccio currently holds positions on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. ASX50 company Sonic Healthcare Limited, ASX-listed Rhythm Non-executive Director.

Peter Hansen

Executive Director
Peter has more than thirty years of experience in founding and leading four biotechnology and medical related companies (Australia, USA and Asia). He has chaired four public companies (Australia and UK) and three IPO’s. His focus on marketing, manufacturing technologies/costs (Australia, Singapore, Malaysia), research collaborations and international licensing.

Ross Williams

Executive Director
Ross is a Chartered Accountant, MBA with over thirty years Finance and Accounting experience in Multinational Public and Private Companies, including then years as GM of a leading Allied Health company. He is a director of Melbourne Stem Cell Centre Research and Australian Osteoarthritis Clinic.
magellan-michael

Michael Kenihan

Executive Director
Michael is past president and CEO of Sports Medicine Australia and a qualified Sports Physiotherapist. Previously GM of Lifecare, a leading Allied Health Company, he is now Director of Melbourne Stem Cell Centre Research and Australian Osteoarthritis Clinic.
magellan-julien

Julien Freitag

Executive Director
Associate Professor Julien Freitag, MBBS, BMedSci is a leading musculoskeletal specialist and sport and exercise physician. He has published numerous internationally regarded journal articles in the area of regenerative medicine. He is the head of Magellan’s Clinical and Scientific Advisory Board.

Management Team

Kiran Shah

Head Scientific Officer
Kiran has significant clinical research experience in biomedical sciences having completed her post-doctoral work at global bio-tech conglomerate CSL within the area of embryonic stem cells and cell culturing. Dr Shah heads Magellan’s R&D and has established their certified Cleanroom Laboratory in Melbourne.
magellan-julien

Julien Freitag

Chief Medical Officer
Associate Professor Julien Freitag, MBBS, BMedSci is a leading musculoskeletal specialist and sport and exercise physician. He has published numerous internationally regarded journal articles in the area of regenerative medicine. He is the head of Magellan’s Clinical and Scientific Advisory Board.
richard-price

Richard Price

Corporate Advisory Board
Richard has had a significant career in the banking sector, including twenty-five with Macquarie Group as an Executive Director providing strategic and financial advice to leading Australian and International companies. He sits as a council member on the National Library of Australia
Renee-Headshot

Renee Castelluccio

Executive Assistant
Renee has background as a practice nurse and experienced clinical and office manager performs the role of coordinating activities of the Board and other senior Management team members. This role extends to coordinating clinical P 1 to P3 trial activities.

Magellan are pleased to announce the results of our Phase 1/2 allogenic trial. The research findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI), which publishes the evidence-based, international consensus guidelines on osteoarthritis management.  

Australian Health Minister announced a $7 million grant to Magellan Stem Cells – read more here

Should you want further information regarding our results or media release please email info@magellanstemcells.com.au or call 03 9270 8080.

Investment Enquiry

Download the full Investor Presentation